Nanosignal (AOBLVV)
Seite 1 von 3 Neuester Beitrag: 25.04.21 13:08 | ||||
Eröffnet am: | 19.01.04 18:08 | von: Meiko | Anzahl Beiträge: | 73 |
Neuester Beitrag: | 25.04.21 13:08 | von: Katharinauvu. | Leser gesamt: | 8.593 |
Forum: | Börse | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 > |
und ich denke zum pushen sollte man woanders hingehen.
Entweder man ist ueberzeugt oder man sollte es lassen.
Gut dass ich heute nachlegen kann....
und hoffe es bleibt noch ne Weile so, solange Werte wie MWG, Morpho, GPC und heute Biolitec und November laufen (kann mir das hier egal sein.....) wobei ich schon dabei bin sowohl tief als hoch!
Was könnte man nicht alles auf Bildern mit dieser Technologie darstellen und was bringt es Unternehmen in der Biotechnologie auf Nanoebene zu projezieren. Nanosignal könnte echt gut laufen.
Ob das so sein wird, weiss ich nicht zu sagen (bin leider kein Hellseher)
Wer kann das wichtigste übersetzen?
NanoSignal Corp. Arrival and Installation of Ballard AirGen Fuel Cell Generators
Thursday January 29, 4:03 pm ET
LAS VEGAS--(BUSINESS WIRE)--Jan. 29, 2004--NanoSignal Corp. (OTC BB: NNOS) is pleased to announce the arrival of the Ballard Power Systems, AirGen fuel cell generators, purchased from Energy Ventures Organization, through the Fuel Cell Store of Boulder, Colo. The AirGen® fuel cell generators are set to be installed on Friday, Jan. 30, 2004, at Desert Radiology.
These units will provide continuous backup power for NanoSignal`s new SLICES(TM) image processing workstations used with magnetic resonance imaging (MRI) systems. These 1 kilowatt AirGen® models will be beta-tested by four MRI sites currently operated at Desert Radiology in Las Vegas. The initial units will be evaluated by NanoSignal Corp.`s (NNOS) research and development division for 45 days. Upon completion of the testing, a determination of the Ballard AirGen® fuel cell generator units will be made and as requirement expectations are met it will be packaged with NanoSignal Corp.`s MRI SLICES(TM) products and included at no extra cost with each SLICES(TM) unit.
NanoSignal`s SLICES(TM) technology features groundbreaking software that manipulates raw data matrices obtained through the MRI scanning process. Through the use of advanced calculations, SLICES(TM) systems produce images that boast up to 10 times more clarity and resolution than standard MRI processing software.
Ballard Power Systems is recognized as the world leader in developing, manufacturing and marketing zero-emission proton exchange membrane fuel cells. Ballard is commercializing fuel cell engines for transportation applications and fuel cell systems for portable and stationary products. Ballard is also commercializing electric drives for fuel cell and other electric vehicles and power conversion products, and is a Tier 1 automotive supplier of friction materials for power train components. Ballard`s proprietary technology is enabling automobile, bus, electrical equipment, portable power and stationary product manufacturers to develop environmentally clean products for sale. Ballard is partnering with strong, world-leading companies, including DaimlerChrysler, Ford, EBARA, ALSTOM and FirstEnergy, to commercialize Ballard® fuel cells. Ballard has supplied fuel cells to Honda, MGE UPS SYSTEMS, Mitsubishi, Nissan, and Volkswagen, among others.
This press release contains " forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the lead-in " Looking Forward." These statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of the effectiveness of management`s strategies and decisions, general economic and business conditions, new or modified statutory or regulatory requirements, and changing price and market conditions. No assurance can be given that these are all the factors that could cause actual results to vary materially from the forward-looking statement.
Betreten Sie NanoSignal Corporation.
SCHEIBEN? eine ist das Groundbreaking Software, die die Matrizen der rohen Daten manipuliert, die durch den MRI Abtastungprozeß erreicht werden. Durch den Gebrauch von vorgerückten Berechnungen (NanoSignals GENAUE Methode), SCHEIBEN? ist, Bilder zu produzieren, die bis 10mal mehr Klarheit und Auflösungen als Standard-MRI sich rühmen, das softwares verarbeitet.
Zusätzlich zur überlegenen Bildqualität und wegen der Methode der Verarbeitung, SCHEIBEN? IST in der Lage, geduldige Scan-Zeit und die Notwendigkeit an den geduldigen Wiederholungsbesuchen und am Wiederablichten erheblich zu verringern. Diese Faktoren können zu einer Verringerung des Filmverbrauchs von bis 40% auch beitragen
Wer hat Informationen über die Finanzlage von NANOSIGNAL?
Advanced Charting - Java Chart - Intraday - View History0.1710.170.18 (50) / 0.19 (50)
View History
Last TradedTransaction VolumeSentiment Stockscore / Rating Learn More -->Buyer (ID) Seller (ID)-->4:06:00 PM EST3,200 -->N/A N/A-->IndustryShares OutstandingMarket CapN/AN/AN/AP / E RatioEPSTrade Now N/A-0.04Choose BrokerageDividendDividend DateYieldN/AN/AN/A
2/5/04
LAS VEGAS, Feb 5, 2004 (BUSINESS WIRE) --
NanoSignal Corp. (formerly MicroSignal Corp.) (OTCBB:NNOS) announced today that it has entered into a consulting agreement with Al Noshirvani to develop sales and marketing of SLICES(TM).
Noshirvani comes to NanoSignal with a wealth of sales and marketing experience.
Noshirvani has been a sales professional in the medical equipment and health industries for over 10 years. Noshirvani will help NanoSignal establish a national distribution network for SLICES(TM). In addition, Noshirvani will implement a best business practices marketing program.
Dr. Lawrence Madoff, president of NanoSignal, stated: 'We are excited to have Al on board. Al was involved during the formative stages of the company's growth and was a shareholder and sales director of MicroSignal when it was a private Pennsylvania company. Al's experience and sales ability will help us take SLICES to the next level.'
Noshirvani stated: 'It is really exciting to join NanoSignal as a consultant. It's like coming full circle when you look at the relationship I had with the company when it was private. I hope to leverage my contacts and experience both past and present to establish SLICES(TM) as a leader in the diagnostic imaging and radiology marketplace.'
Noshirvani has scheduled a SLICES(TM) sales and marketing seminar for the beginning of March 2004 in Las Vegas.
In related hiring, NanoSignal is pleased to announce that Felicia Browell has been hired to design a professionally written user manual for SLICES(TM). Browell will consult with Dr. Jeffrey Taft, Chris Puleo and Sherry Yavelak in accomplishing this project. Browell started writing technical documentation in 1987 and she specializes in software manuals and tutorials. Browell's most recent work documented several features in a complex finite element analysis (FEA) engineering software suites. Browell has a strong interest in medicine and she is looking forward to helping NanoSignal create comprehensive documentation that will help SLICES(TM) become recognized as a leader in user-friendly software products for the MRI industry.
Browell has a strong interest in medicine and she is looking forward to helping NanoSignal create comprehensive documentation that will help SLICES(TM) become recognized as a leader in user-friendly software products for the MRI industry.
SK 3.2.04 0,180 $
SK 4.2.04 0,171 $
SK 5.2.04 0,185 $ + 8,19 %
SK 6.2 04 0,190 $ + 2,70 %
NanoSignal Corp. -- Formerly MicroSignal -- Reports Successful Beta Testing Results of SLICES, Sales &Marketing and Other Significant Developments 2/11/04 | ||
LAS VEGAS, Feb 11, 2004 (BUSINESS WIRE) -- NanoSignal Corp. (formerly Microsignal Corp.) (OTCBB:NNOS) reported today the highly successful and industry significant completion of the first phase of beta testing of SLICES(TM) software technology for MRI devices at Desert Radiology in Las Vegas, NV. Dr. Lawrence 'Working with a standard 1.5 Tesla General Electric MRI scanner at Desert Radiology, we used SLICES(TM) to maintain signal noise and resolution in less than 50% of the usual scanning time while at the same time producing clear images suitable for radiological interpretation. This achievement is industry historic since it demonstrates that SLICES(TM) software not only works but works in half of the time. This means that patient pass through is increased resulting in medical cost savings and greater human comfort since time in the tunnel can be greatly shortened.' Our engineering team will continue beta testing at Desert Radiology over the next several weeks on both GE and other MRI devices manufactured by the leading companies in the business. Our objectives will be to increase resolution and improve image quality on all MRI devices, both tunnel configuration and the highly popular open MRI's. Testing of SLICES(TM) integration with DICOM compatible PACS systems is progressing with a high degree of satisfaction. Significantly, our technical 'White Paper'will include both the beta test results for SLICES(TM), a marketing plan, financial forecasts and statistical data for health insurers proving the cost benefits of SLICES(TM). We will be assisted by Ali Noshirvani, who has been selected to head-up sales and marketing, as previously announced in our Business Wire press release dated Feb. 5, 2004. We further anticipate ramping up a recruitment program for additional software engineers and installation technicians. With beta testing near completion, our message to the MRI industry is that up-grading MRI devices with the new SLICES(TM) software versus the capital outlay for costlier MRI equipment is now a real choice. Given the size and depth of the MRI industry, we are open to multiple distribution channels such as direct sales, co-branding, sub-licensing and strategic alliances with MRI manufacturers. The best thing for our shareholders is to make SLICES(TM) the software of choice for all MRI manufacturers to replace the outdated image processing methodologies that is decades old. Everyone knows how successful 'red eye'reduction has been to the camera and film industry. Now with SLICES(TM), MRI facilities have a one stop purchase to reduce artifacts and ghosting on images with increased productivity that pays for the software outlay. The company has been in negotiations with multiple investment banking firms to meet its anticipated funding needs for national and international sales and marketing in 2004-2005. In order to concentrate on the beta testing and the medical applications of SLICES(TM), Dr. Madoff will continue as President of NanoSignal with the additional title of Chief Operating Officer. The Board of Directors and majority preferred shareholder have unanimously selected Scott Ervin to take on the responsibilities of Chief Executive Officer. Scott is a welcome member of the NanoSignal team and he will be instrumental in meeting the global demand for SLICES(TM). Scott Erwin has enjoyed an impressive career in real estate management, finance, mergers-acquisitions and leasing with a number Fortune 500 caliber companies including the First Boston Corporation, Fisher Brothers, and Rockefeller Center, Inc. In November 2003, Mr. Erwin became President and CEO of Micro Bio-Medical Systems, Inc., a position which he will continue to hold indefinitely. Additional information regarding SLICES(TM) and NanoSignal Corp. is available at www.nanosignalcorp.com. |
OVERALL OPERATING RESULTS:
The Company plans to seek financing and capital to allow it to exploit this technology as well as to enhance and improve on this technology. During 2003, the Company intends to seek the necessary financing to allow it to implement its business plan and to commence operations in a meaningful way.
We have had no revenues for the three and nine months ended September 30, 2003 and 2002, respectively.
Our operating expenses for the quarter ended September 30, 2003 were $204,321 and were primarily incurred for salaries, consulting, rent and other services rendered in connection with our financial reporting obligations with the Securities and Exchange Commission as well as stock transfer agent fees and financial consulting. Operating expenses for the prior year quarter ended September 30, 2002 totaled $0.
Our operating expenses for the nine months ended September 30, 2003 were $641,665 and were primarily incurred for salaries, consulting, rent and other services rendered in connection with our financial reporting obligations with the Securities and Exchange Commission as well as stock transfer agent fees. Operating expenses for the nine months ended September 30, 2002 totaled $2,656 for general expenses.
LIQUIDITY AND CAPITAL RESOURCES:
The Company has approximately $10,000 in current assets compared to current assets of approximately $2,000 for the year ended December 31, 2002. The Company's current liabilities for the period ended September 30, 2003 are approximately $3,336,000 compared to current liabilities of approximately $2,960,000 for the year ended December 31, 2002. The current assets for the period ended September 30, 2003 consisted of cash of $4,650. Total assets were approximately $12,000 for the year ended December 31, 2002 composed of the Company's patent of approximately $9,500 and its cash.
At September 30, 2003, the Company had negative working capital of approximately $3,326,000 which consisted of current assets of approximately $10,000 and current liabilities of approximately $3,336,000. At December 31, 2002, the Company had negative working capital of approximately $2,961,000 which consisted of current assets of approximately $2,000 assets and current liabilities of approximately $2,963,000. The current liabilities of the Company at September 30, 2003 are composed primarily of notes payable to shareholders of $1,367,650, notes payable of $774,339, accrued interest payable of $877,571, accrued expenses of $169,610, lease payable of $38,650, deposits of $40,000 and accounts payable of $68,503.
The Company will attempt to carry out its business plan as discussed above. The Company cannot predict to what extent its lack of liquidity and capital resources will hinder its business plan prior to commencement of its proposed operations.
NEED FOR ADDITIONAL FINANCING
The Company's existing capital is not be sufficient to meet the Company's cash needs, including the costs of compliance with the continuing reporting requirements of the Securities Exchange Act of 1934, as amended.
No commitments to provide additional funds have been made by management or other stockholders. Accordingly, there can be no assurance that any funds will be available to the Company to allow it to cover its expenses.
The Company might seek to compensate providers of services by issuances of stock in lieu of cash.
Employees
As of September 30, 2003, the Company had three employees.